Figure 1. Blockade of LT/LIGHT inhibits disease progression and extends the survival of Rag1^–/– mice after HSV-1 infection.

(a) Rag1^–/– mice (n = 6/group) were infected with 2 × 10⁶ pfu of HSV-1 and treated with 100 ug of LTβR-Ig or control protein on day -1 and day 5 p.i. (b, c) Rag1^–/– LIGHT^+/+ or Rag^–/–LIGHT^–/– mice (n = 3 to 5/group) were infected with 2 × 10⁶ pfu of HSV-1 and treated with LTβR-Ig (b), anti-LTβ (c) or control protein as indicated. Anti-LTβ was administrated at 250 ug/mice every 3 days starting from day -1. Mice were observed for the development of skin lesion, general behavioral changes and survival. The severity of morbidity was scored as follows: 0+, normal; 1+, footpad swell; 2+, show ulceration in the skin of thigh; 3+, tail incline to one side or paralysis; 4+, moribund mice which were euthanized. The pathology score at the indicated time points are shown. Ctr Ig, control protein. Data are representative of more than three (a) or two (b, c) independent experiments. Statistical analysis for survival data was by log rank test.